| Abstrakt: |
To develop a passively targeted, patient‐compliant, intranasal interleukin‐10 (IL‐10) gene therapy delivery system and to investigate its therapeutic benefit in experimental collagen‐induced arthritis, a model of rheumatoid arthritis. Arthritis was induced in DBA/1 mice and monitored following intranasal administration of an IL‐10 plasmid (pG‐IL‐10) or the empty vector 2 days (days −2 and 19) prior to collagen injection (prophylactic group, as a single dose after collagen boost on day 21 (early therapy group, or as a single dose upon acquisition of a disease score of 3 (late therapy group. IL‐10–induced alterations in cytokine secretion and proliferation by spleen and lymph node cells were assessed on days 31 and 65 and correlated with histologic changes and bone erosions assessed on day 65.Intranasal delivery of pG‐IL‐10 significantly delayed arthritis onset and reduced disease severity in the prophylactic group and early therapy group, reduced cellular infiltration and bone loss in the early therapy group, and reduced T cell proliferation in response to collagen on days 31 and 65 in these two groups, with a significant reduction in tumor necrosis factor α production on day 65. Within the late therapy group, disease progression was arrested for the rest of the study. The intranasally administered pG‐IL‐10 targeted monocytes and macrophages and showed dissemination to inflamed joints and draining lymph nodes in vivo. Importantly, systemic levels of IL‐10 (in serum) were transient (peaking on day 2) and undetectable by day 4.Intranasal IL‐10 gene delivery significantly reduces bone destruction, shows evidence of reducing joint inflammation, and may be mediated by high local levels of IL‐10 produced by transfected monocytes trafficking to inflamed joints and draining lymph nodes. [ABSTRACT FROM AUTHOR] |
Plný text